Curcumin Dually Inhibits Both Mammalian Target of Rapamycin and Nuclear Factor-κB Pathways through a Crossed Phosphatidylinositol 3-Kinase/Akt/IκB Kinase Complex Signaling Axis in Adenoid Cystic Carcinoma
Authors:
- Gang ChenGCGang Chen
- Wei ZhangWZWei Zhang
- Xiang HuXHXiang Hu
- Yang LiuYLYang Liu
- Qian ZhouQZQian Zhou
- Ling-Xing ZhuLZLing-Xing Zhu
- Yi-Fang ZhaoYZYi-Fang Zhao
- 1 January 2011
- journal article
- research article
- Published by Elsevier in Molecular Pharmacology
- Vol. 79 (1) , 106-118
Abstract
Adenoid cystic carcinoma (ACC) is a highly malignant tumor that is generally unresponsive or only weakly responsive to the currently available antineoplastic agents. Thus, novel therapeutic strategies and agents are urgently needed to treat this aggressive neoplasm. Curcumin, a component of turmeric (Curcuma longa), has been shown to have a diversity of antitumor activities. We show here that curcumin is a potent inhibitor of ACC progression in vitro and in vivo. Curcumin concentration-dependently inhibited the growth of ACC cells via induction of apoptosis. The ability of ACC cells to migrate/invade and induce angiogenesis was also significantly attenuated by curcumin, accompanied by the down-regulation of vascular endothelial growth factor (VEGF) and matrix metalloproteinase-2 and -9. Moreover, our data also demonstrated that the inhibitory effects of curcumin on ACC cells were due to its dual inhibition of both mammalian target of rapamycin (mTOR) and nuclear factor-κB (NF-κB) pathways through a crossed phosphatidylinositol 3-kinase/Akt/IκBα kinase signaling axis. Most importantly, curcumin effectively prevented the in vivo growth and angiogenesis of ACC xenografts in nude mice, as revealed by the induction of cell apoptosis and reduction of microvessel density in tumor tissues. In addition, we further assessed the nature activation status of both mTOR and NF-κB pathways in ACC tissues and confirmed the concurrent high activation of these two pathways in ACC for the first time. Taken together, our findings suggest that further clinical investigation is warranted to apply curcumin as a novel chemotherapeutic regimen for ACC because of its dual suppression of both mTOR and NF-κB pathways.Keywords
This publication has 34 references indexed in Scilit:
- Curcumin and cancer: An “old-age” disease with an “age-old” solutionCancer Letters, 2008
- Phase II Trial of Curcumin in Patients with Advanced Pancreatic CancerClinical Cancer Research, 2008
- Curcumin as “Curecumin”: From kitchen to clinicBiochemical Pharmacology, 2008
- Curcumin inhibits connective tissue growth factor gene expression in activated hepatic stellate cellsin vitroby blocking NF‐κB and ERK signallingBritish Journal of Pharmacology, 2008
- Defining the Role of mTOR in CancerCancer Cell, 2007
- Curcumin inhibits the mammalian target of rapamycin‐mediated signaling pathways in cancer cellsInternational Journal of Cancer, 2006
- Curcumin (Diferuloylmethane) Down-Regulates Expression of Cell Proliferation and Antiapoptotic and Metastatic Gene Products through Suppression of IκBα Kinase and Akt ActivationMolecular Pharmacology, 2006
- Curcumin Suppresses the Paclitaxel-Induced Nuclear Factor-κB Pathway in Breast Cancer Cells and Inhibits Lung Metastasis of Human Breast Cancer in Nude MiceClinical Cancer Research, 2005
- Adenoid Cystic Carcinoma of the Head and NeckJAMA Otolaryngology–Head & Neck Surgery, 1999
- Selection of adenoid cystic carcinoma cell clone highly metastatic to the lung: an experimental studyInternational Journal of Oral and Maxillofacial Surgery, 1997